Published in Cancer Weekly, March 10th, 1997
Hemolink is a red blood cell substitute product. Alun Davies, Hemosol, said that the initial stage of the trials was planned for performance in a Toronto-area hospital. "This is a watershed event for us and particularly satisfying since Hemolink is the first hemoglobin-based oxygen carrier to be approved for Phase II trials in Canada by regulatory authorities," said Davies.
"Our continuing animal studies have confirmed our belief that Hemolink has a clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.